Search research articles
Contact Us
Filters
Showing results (51-60 of 61) with videos related to
Page
of 7
Sort By:
British Journal of Cancer
|
May 29, 2003
A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs
R A Spooner, F Friedlos, K Maycroft, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2017
Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma
R J Lee, G Gremel, A Marshall, et al.
The EMBO Journal
|
March 16, 2000
The endocytic protein intersectin is a major binding partner for the Ras exchange factor mSos1 in rat brain
X K Tong, N K Hussain, E de Heuvel, et al.
Leukemia
|
January 18, 2014
A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages
D Gentien, O Kosmider, F Nguyen-Khac, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 16, 2017
The European Society for Medical Oncology (ESMO) Precision Medicine Glossary
L R Yates, J Seoane, C Le Tourneau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA
G Gremel, R J Lee, M R Girotti, et al.
British Journal of Cancer
|
August 2, 2006
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T Eisen, T Ahmad, K T Flaherty, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 5, 2016
Consensus on precision medicine for metastatic cancers: a report from the MAP conference
C Swanton, J-C Soria, A Bardelli, et al.
British Journal of Cancer
|
July 14, 2011
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
T Eisen, R Marais, A Affolter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 1, 2020
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
G Saturno, F Lopes, I Niculescu-Duvaz, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 61) with videos related to
Sort By:
Page
of 7
British Journal of Cancer
|
May 29, 2003
A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs
R A Spooner, F Friedlos, K Maycroft, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2017
Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma
R J Lee, G Gremel, A Marshall, et al.
The EMBO Journal
|
March 16, 2000
The endocytic protein intersectin is a major binding partner for the Ras exchange factor mSos1 in rat brain
X K Tong, N K Hussain, E de Heuvel, et al.
Leukemia
|
January 18, 2014
A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages
D Gentien, O Kosmider, F Nguyen-Khac, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 16, 2017
The European Society for Medical Oncology (ESMO) Precision Medicine Glossary
L R Yates, J Seoane, C Le Tourneau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA
G Gremel, R J Lee, M R Girotti, et al.
British Journal of Cancer
|
August 2, 2006
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T Eisen, T Ahmad, K T Flaherty, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 5, 2016
Consensus on precision medicine for metastatic cancers: a report from the MAP conference
C Swanton, J-C Soria, A Bardelli, et al.
British Journal of Cancer
|
July 14, 2011
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
T Eisen, R Marais, A Affolter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 1, 2020
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
G Saturno, F Lopes, I Niculescu-Duvaz, et al.
Page
of 7